

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技术有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 00241)

CHANGE OF CHIEF EXECUTIVE OFFICER AND AUTHORIZED REPRESENTATIVE

APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND AUTHORIZED REPRESENTATIVE

The board (the “**Board**”) of directors (the “**Directors**”) of Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, Mr. Shen Difan (“**Mr. Shen**”), executive Director of the Company, has been appointed as the chief executive officer of the Company (the “**Chief Executive Officer**”) and one of the authorized representatives of the Company under the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), with effect from the close of business on November 28, 2023.

The biography of Mr. Shen is set out below:

Shen Difan, aged 45, had held various positions in Alibaba Group (as defined below) since he joined in 2004, which mainly included the following: Mr. Shen has served as an executive Director of the Group since October 13, 2021. Mr. Shen currently also serves as a director of certain subsidiaries of the Company. From October 2020 to November 28, 2023, he served as the chief operating officer of the Group. He was a special assistant to the chairman of the board of directors of Alibaba Group Holding Limited (together with its subsidiaries, “**Alibaba Group**”) from March 2020 to October 2021, and served as an executive Director and the Chief Executive Officer of the Group from March 2018 to March 2020. He was the general manager of Alibaba Group’s AliExpress business from March 2012 to March 2018, leading the rapid expansion of AliExpress and growing Alibaba Group’s overseas brand influence. Mr. Shen holds a Bachelor Degree in Computing from Yantai University.

As at the date of this announcement, Mr. Shen beneficially held 1,168,043 ordinary shares of the Company and subject to vesting, he is interested in 3,609,525 shares underlying the 2,702,250 options and 907,275 restricted share units granted to him in accordance with the Company's share award scheme.

Save as disclosed herein and as at the date of this announcement, Mr. Shen (i) is not interested or deemed to be interested in any shares or underlying shares of the Company pursuant to Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iii) does not hold any directorship in any other Hong Kong or overseas listed public companies in the last three years preceding the date of this announcement, or any other position with the Company or other members of the Group.

Mr. Shen has entered into an appointment letter as an executive Director with the Company for a term of one year commenced from October 13, 2023, which is renewable for a one-year period upon expiry of each term. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the provisions of the bye-laws of the Company and the Listing Rules. There is no separate service contract in relation to Mr. Shen's appointment as the Chief Executive Officer. Mr. Shen's remuneration package shall remain the same following his appointment as the Chief Executive Officer.

Save as disclosed herein, Mr. Shen has confirmed that there is no other information required to be disclosed in accordance with Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter relating to his appointment as the Chief Executive Officer that needs to be brought to the attention of the shareholders of the Company (the "Shareholders").

The Board would like to congratulate Mr. Shen on his new appointment.

RESIGNATION OF CHIEF EXECUTIVE OFFICER AND AUTHORIZED REPRESENTATIVE

The Board announces that for the purpose of focusing on the Group's long-term strategic development plan, Mr. Zhu Shunyan ("Mr. Zhu") has tendered his resignation as the Chief Executive Officer and will cease to act as one of the authorized representatives of the Company under the Listing Rules, with effect from the close of business on November 28, 2023 (the "Resignation") and will remain as an executive Director, the chairman of the Board and the chairman of the nomination committee of the Company.

Mr. Zhu has confirmed that there are no disagreements with the Board, and there are no matters in relation to his Resignation that need to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its appreciation for the valuable contributions made by Mr. Zhu to the Company during his tenure of service as the Chief Executive Officer.

For and on behalf of the Board
Alibaba Health Information Technology Limited
Zhu Shunyan
Chairman

Hong Kong, November 28, 2023

As at the date of this announcement, the Board comprises Mr. Zhu Shunyan, Mr. Shen Difan and Mr. Tu Yanwu as the executive Directors; Ms. Huang Jiaojiao and Mr. Xu Haipeng as the non-executive Directors; and Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong as the independent non-executive Directors.